{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-012870","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.544340+00:00","generated_at":"2026-05-26T22:56:07.564844+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INmune Bio completes Phase I dose cohort for INKmune in mCRPC, opens Phase II","bullets":["Third and highest dose cohort of Phase I completed; no safety issues found.","Scientific Review Committee unanimously voted to open all Phase II cohorts of CaRePC trial.","Low dose cohort showed immunologic effects; higher dose cohorts to assess therapeutic benefits.","CEO R.J. Tesi noted INKmune given in outpatient setting with exemplary safety profile.","CSO Mark Lowdell invited to speak at 10th Annual Innate Killer Summit on March 4."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-012870","json":"https://secwatch.observer/filing/0001213900-25-012870.json","markdown":"https://secwatch.observer/filing/0001213900-25-012870.md","text":"https://secwatch.observer/filing/0001213900-25-012870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025012870/0001213900-25-012870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025012870/ea0230833-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:56:07.564844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}